Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Boston Scientific Corp. posted another eye-popping quarterly report, led by a 177% year-over-year increase in its ...

Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation beats earnings expectations. Reported EPS is ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

That was his first sign of AFib. After a failed traditional ablation procedure, Copley was one of the first to have Farapulse ...

Mizuho raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares post the ...